The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.
 
Christine Chevreau
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Aude Flechon
No Relationships to Disclose
 
Remy Delva
No Relationships to Disclose
 
Gwenaelle Gravis
No Relationships to Disclose
 
Jean-Pierre Lotz
No Relationships to Disclose
 
Jacques-Olivier Bay
No Relationships to Disclose
 
Marine Gross-Goupil
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Loic Mourey
No Relationships to Disclose
 
Fabienne Thomas
No Relationships to Disclose
 
Thomas Filleron
No Relationships to Disclose
 
Pascale Olivier
No Relationships to Disclose
 
Stephane Culine
No Relationships to Disclose
 
Etienne Chatelut
No Relationships to Disclose